Altimmune, Inc. (ALT)

Market Cap	359.21M
Revenue (ttm)	20,000
Net Income (ttm)	-87.75M
Shares Out	88.26M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,020,116
Open	4.050
Previous Close	4.000
Day's Range	4.020 - 4.250
52-Week Range	2.900 - 11.160
Beta	0.06
Analysts	Strong Buy
Price Target	16.50 (+305.41%)
Earnings Date	Nov 6, 2025

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ALT
• Website: https://altimmune.com

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 305.41% from the latest price.

Price Target

$16.5

(305.41% upside)

Analyst Consensus: Strong Buy